Showing results (191-200 of 251) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2018
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trialJ K Mooi, P Wirapati, R Asher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyE Van Cutsem, T Yoshino, H J Lenz, et al.
Acta Gastro-Enterologica Belgica|November 23, 2011
Quality of care indicators in rectal cancerP Demetter, W Ceelen, E Danse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyJ Tabernero, R R Hozak, T Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinomaK Shitara, M Özgüroğlu, Y-J Bang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2014
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyE Van Cutsem, C Boni, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
British Journal of Cancer|March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsE Van Cutsem, P M Hoff, P Harper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Pageof 26